Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy

While the majority of thyroid cancer patients are easily treatable, those with anaplastic or poorly differentiated recurrent thyroid carcinomas have a very poor prognosis with a median survival of less than a year. Previously, we have shown a significant correlation between ICAM-1 overexpression and...

Descripción completa

Detalles Bibliográficos
Autores principales: Vedvyas, Yogindra, McCloskey, Jaclyn E., Yang, Yanping, Min, Irene M., Fahey, Thomas J., Zarnegar, Rasa, Hsu, Yen-Michael S., Hsu, Jing-Mei, Besien, Koen Van, Gaudet, Ian, Law, Ping, Kim, Nak Joon, Hofe, Eric von, Jin, Moonsoo M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6650612/
https://www.ncbi.nlm.nih.gov/pubmed/31337787
http://dx.doi.org/10.1038/s41598-019-46938-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6650612/
https://www.ncbi.nlm.nih.gov/pubmed/31337787
http://dx.doi.org/10.1038/s41598-019-46938-7

Ejemplares similares